reports
- Guy Sips
- Hilde Van Boxstael
- Sharad Kumar S.P
- Thomas Vranken
- Wim Lewi
- Thomas Vranken
Biotalys FIRST LOOK: Fresh cash through € 15m private placement
Biotalys raises € 15m through a private placement with a strong syndicate of existing investors AvH and AIF, as well as new investor ASR. The new shares are issued at € 2.83, representing a discount of 10% on the 30-day VWAP. Proceeds will be used to support Evoca's regulatory filing, advance the pipeline and strengthen the Agrobody platform. We expect the additional funds to extend the cash runway by approx. 4 quarters into mid-2026 (KBCSe), and in the meantime continue to look out for EPA appr...
- Thomas Vranken
Biotalys FIRST LOOK: BioFun-8 strengthens the pipeline
Biotalys announced the addition of a new biofungicide program to the pipeline. Biofun-8 leverages Biotalys' Agrobody platform and will target Alternaria, an important leaf spot fungus in fruits, vegetables and potato crops. Biotalys estimates a market opportunity around $ 1.1bn. We reiterate our € 6 TP and Buy rating.
- Jacob Mekhael
- Thomas Vranken
- Wim Hoste
- Guy Sips
- Hilde Van Boxstael
- Lynn Hautekeete
- Thibault Leneeuw
- Wim Hoste
- Wim Lewi
- Guy Sips
- Hilde Van Boxstael
- Thibault Leneeuw
- Thomas Couvreur
- Thomas Vranken
- Wim Hoste
- Thomas Vranken
Biotalys FIRST LOOK: 1H24: Programs on track, Dutch demo kickstarts
Biotalys continues its work with the EPA and Ctgb for regulatory approval of Evoca in the US and EU. Impressively, Evoca can start a large-scale demo trial in the Netherlands with allowed harvest sale for human consumption, which we see as a major vote of confidence by the regulator. Overall, Biotalys is advancing on its key programs despite a significqnt opex cut, leaving runway into 2Q25. We maintain our conviction in Biotalys' tech while we await a regulatory decision, and reiterate a € 6.0 T...
- Thomas Couvreur
- Thomas Vranken
- Wim Hoste
- Wim Lewi
- Jacob Mekhael
- Thomas Vranken
- Guy Sips
- Hilde Van Boxstael
- Wim Lewi
- Guy Sips
- Thomas Vranken
Biotalys A llama-inspired way to protect crops
Biotalys uses large molecule antibody technology from the pharmaceutical industry to develop innovative crop protection solutions. Its first product, the biofungicide Evoca, is derived from the AGROBODY Foundry platform and targets the high-growth biological crop protection market. Biotalys focuses on cost-effective R&D to introduce new modes of action in fungicides and insecticides, with regulatory processes in the US and EU progressing. It has commercial agreements in place for production and ...
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Lynn Hautekeete
- Michiel Declercq
- Thomas Couvreur
- Wim Hoste
- Wim Lewi
- Guy Sips
- Hilde Van Boxstael
- Lynn Hautekeete
- Thomas Vranken
- Wim Lewi
- Guy Sips
Biotalys Manufacturing/commercialisation partnership for Evoca NG with...
We welcome Biotalys and Novonesis announced a manufacturing and commercialisation partnership for Evoca NG. Leveraging Novonesis' world leading fermentation capabilities can not only add value to Biotalys' very promising Agrobody technology but (as Novonesis is one of the leaders in the field of biosolutions) this can as well be seen as an important step forward for Biotalys as they lay the foundation for future commercial launches from its Agrobody 2.0 technology platform. We reiterate our Buy ...
- Guy Sips
- Hilde Van Boxstael
- Kristof Samoy
- Lynn Hautekeete
- Sharad Kumar S.P
- Thibault Leneeuw
- Thomas Vranken
- Wim Lewi
- Guy Sips
- Thomas Vranken
Biotalys FIRST LOOK : FY23 results, ready at the starting blocks
No major surprises out of Biotalys' FY23 update as the company continues its work with the EPA for regulatory approval of Evoca. Meanwhile, new management fine-tuned the technology platform and restructured the pipeline with BioFun-6 now coming forward as the next candidate for field trials. Cash landed higher than expected at € 21.6m, implying runway until April 2025. We maintain our conviction in Biotalys' technology while we await a regulatory decision, and reiterate our € 6.0 TP and Buy rati...
- Guy Sips
- Hilde Van Boxstael
- Thomas Couvreur
- Thomas Vranken
- Wim Hoste
- Wim Lewi
- Guy Sips
- Kristof Samoy
- Thomas Vranken
- Guy Sips
- Sharad Kumar S.P
- Wim Lewi
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.